[SCHEDULE 13G/A] ReShape Lifesciences, Inc. SEC Filing
ReShape Lifesciences received an amended Schedule 13G from L1 Capital Global Opportunities Master Fund, Ltd. reporting beneficial ownership of 7,862 shares of common stock underlying warrants, representing 0.33% of the class based on 2,385,960 shares outstanding after the offering referenced in the issuer's June 9, 2025 prospectus supplement. The filing states the shares are held by the Cayman Islands entity and clarifies that David Feldman and Joel Arber are directors of the reporting fund and may be deemed to beneficially own the securities but disclaim such ownership for other purposes. The filing affirms the position is not intended to influence control of the issuer.
ReShape Lifesciences ha ricevuto un emendamento al Schedule 13G da parte di L1 Capital Global Opportunities Master Fund, Ltd., che dichiara la titolarit脿 beneficiaria di 7.862 azioni ordinarie sottostanti warrant, pari a 0,33% della categoria su un totale di 2.385.960 azioni in circolazione dopo l'offerta indicata nel supplemento al prospetto del 9 giugno 2025. Il deposito specifica che le azioni sono detenute dall'entit脿 delle Isole Cayman e chiarisce che David Feldman e Joel Arber sono amministratori del fondo segnalante e potrebbero essere considerati beneficiari dei titoli, pur disconoscendone la propriet脿 per altri fini. Si precisa inoltre che la posizione non 猫 intesa a influenzare il controllo dell'emittente.
ReShape Lifesciences recibi贸 un enmienda al Schedule 13G presentada por L1 Capital Global Opportunities Master Fund, Ltd., que informa la titularidad beneficiaria de 7.862 acciones ordinarias subyacentes a warrants, lo que representa 0,33% de la clase sobre 2.385.960 acciones en circulaci贸n tras la oferta mencionada en el suplemento del prospecto del emisor del 9 de junio de 2025. La presentaci贸n indica que las acciones est谩n en poder de la entidad de las Islas Caim谩n y aclara que David Feldman y Joel Arber son directores del fondo declarante y podr铆an considerarse beneficiarios de los valores, aunque niegan dicha propiedad a otros efectos. Se afirma asimismo que la posici贸n no pretende influir en el control del emisor.
ReShape Lifesciences電� L1 Capital Global Opportunities Master Fund, Ltd.搿滊秬韯� 靾橃爼霅� Schedule 13G毳� 鞝戩垬頄堨溂氅�, 攴� 靹滊電� 鞗岆煱韸胳棎 旮办磮頃� 氤错喌欤� 7,862欤检棎 雽�頃� 靾橃澋鞝� 靻岇湢甓岇潉 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 鞚措姅 氚滍枆須岇偓鞚� 2025雲� 6鞗� 9鞚� 靻岇眳鞛� 氤挫订靹滌棎靹� 鞏戈笁霅� 瓿惦 頉� 氚滍枆欤检嫕靾� 2,385,960欤茧ゼ 旮办鞙茧 韥措灅鞀れ潣 0.33%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊電� 頃措嫻 欤检嫕鞚� 旒�鞚措Ж鞝滊弰 氩曥澑 氇呾潣搿� 氤挫湢霅橁碃 鞛堨潓鞚� 氇呾嫓頃橁碃, David Feldman瓿� Joel Arber電� 氤搓碃 韼�霌滌潣 鞚挫偓搿滌劀 歃濌秾鞚� 靾橃澋鞝� 靻岇湢鞛愲澕瓿� 臧勳＜霅� 靾� 鞛堨溂雮� 雼るジ 氇╈爜靸� 攴� 靻岇湢毳� 攵�鞚疙暅雼り碃 氚濏様鞀惦媹雼�. 霕愴暅 鞚� 韽靺橃潃 氚滍枆鞚胳潣 歆�氚办棎 鞓來枼鞚� 氙胳範 鞚橂弰臧� 鞎勲嫎鞚� 頇曥澑頄堨姷雼堧嫟.
ReShape Lifesciences a re莽u un Schedule 13G amend茅 de la part de L1 Capital Global Opportunities Master Fund, Ltd., d茅clarant la propri茅t茅 b茅n茅ficiaire de 7 862 actions ordinaires sous-jacentes 脿 des warrants, repr茅sentant 0,33 % de la cat茅gorie sur la base de 2 385 960 actions en circulation apr猫s l'offre mentionn茅e dans le suppl茅ment au prospectus de l'茅metteur dat茅 du 9 juin 2025. Le d茅p么t pr茅cise que les actions sont d茅tenues par l'entit茅 des 卯les Ca茂mans et clarifie que David Feldman et Joel Arber sont administrateurs du fonds d茅clarant et peuvent 锚tre r茅put茅s d茅tenir b茅n茅ficiairement les titres, tout en d茅clinant toutefois cette propri茅t茅 脿 d'autres fins. Il est en outre confirm茅 que la position n'a pas pour but d'influencer le contr么le de l'茅metteur.
ReShape Lifesciences erhielt eine ge盲nderte Schedule-13G-Meldung von L1 Capital Global Opportunities Master Fund, Ltd., die den wirtschaftlichen Eigentum an 7.862 Stammaktien, die Optionsscheinen zugrunde liegen, meldet, was 0,33 % der Klasse auf Basis von 2.385.960 ausstehenden Aktien nach dem in der Prospektnachschrift des Emittenten vom 9. Juni 2025 genannten Angebot entspricht. Die Meldung gibt an, dass die Aktien von der Kaiman-Inseln-Gesellschaft gehalten werden, und stellt klar, dass David Feldman und Joel Arber Direktoren des meldenden Fonds sind und als wirtschaftliche Eigent眉mer der Wertpapiere gelten k枚nnten, diese Eigent眉merschaft jedoch f眉r andere Zwecke bestreiten. Weiterhin wird best盲tigt, dass die Position nicht dazu bestimmt ist, die Kontrolle 眉ber den Emittenten zu beeinflussen.
- Transparent disclosure of position size and that holdings are comprised of shares underlying warrants
- Passive intent declared via Schedule 13G certification indicating no attempt to influence control
- None.
Insights
Small passive stake disclosed; immaterial to capital structure.
The filing reports a 7,862-share position via warrants equal to 0.33% of ReShape's post-offering share count. For investors, this size is below material thresholds and unlikely to affect liquidity, voting outcomes, or valuation. The use of Schedule 13G and the certification language indicate a passive, non-control intent. The disclosure of underlying warrant exposure is useful for clarity but does not change near-term financial metrics.
Procedural disclosure; no control implications stated.
The filer affirms the position is held without intent to influence control and files under the passive Schedule 13G framework. Identification of directors of the reporting fund and their disclaimer of beneficial ownership for other purposes is standard governance disclosure. There is no indication of group formation or coordinated activity. From a governance perspective, this is routine compliance communication.
ReShape Lifesciences ha ricevuto un emendamento al Schedule 13G da parte di L1 Capital Global Opportunities Master Fund, Ltd., che dichiara la titolarit脿 beneficiaria di 7.862 azioni ordinarie sottostanti warrant, pari a 0,33% della categoria su un totale di 2.385.960 azioni in circolazione dopo l'offerta indicata nel supplemento al prospetto del 9 giugno 2025. Il deposito specifica che le azioni sono detenute dall'entit脿 delle Isole Cayman e chiarisce che David Feldman e Joel Arber sono amministratori del fondo segnalante e potrebbero essere considerati beneficiari dei titoli, pur disconoscendone la propriet脿 per altri fini. Si precisa inoltre che la posizione non 猫 intesa a influenzare il controllo dell'emittente.
ReShape Lifesciences recibi贸 un enmienda al Schedule 13G presentada por L1 Capital Global Opportunities Master Fund, Ltd., que informa la titularidad beneficiaria de 7.862 acciones ordinarias subyacentes a warrants, lo que representa 0,33% de la clase sobre 2.385.960 acciones en circulaci贸n tras la oferta mencionada en el suplemento del prospecto del emisor del 9 de junio de 2025. La presentaci贸n indica que las acciones est谩n en poder de la entidad de las Islas Caim谩n y aclara que David Feldman y Joel Arber son directores del fondo declarante y podr铆an considerarse beneficiarios de los valores, aunque niegan dicha propiedad a otros efectos. Se afirma asimismo que la posici贸n no pretende influir en el control del emisor.
ReShape Lifesciences電� L1 Capital Global Opportunities Master Fund, Ltd.搿滊秬韯� 靾橃爼霅� Schedule 13G毳� 鞝戩垬頄堨溂氅�, 攴� 靹滊電� 鞗岆煱韸胳棎 旮办磮頃� 氤错喌欤� 7,862欤检棎 雽�頃� 靾橃澋鞝� 靻岇湢甓岇潉 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 鞚措姅 氚滍枆須岇偓鞚� 2025雲� 6鞗� 9鞚� 靻岇眳鞛� 氤挫订靹滌棎靹� 鞏戈笁霅� 瓿惦 頉� 氚滍枆欤检嫕靾� 2,385,960欤茧ゼ 旮办鞙茧 韥措灅鞀れ潣 0.33%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊電� 頃措嫻 欤检嫕鞚� 旒�鞚措Ж鞝滊弰 氩曥澑 氇呾潣搿� 氤挫湢霅橁碃 鞛堨潓鞚� 氇呾嫓頃橁碃, David Feldman瓿� Joel Arber電� 氤搓碃 韼�霌滌潣 鞚挫偓搿滌劀 歃濌秾鞚� 靾橃澋鞝� 靻岇湢鞛愲澕瓿� 臧勳＜霅� 靾� 鞛堨溂雮� 雼るジ 氇╈爜靸� 攴� 靻岇湢毳� 攵�鞚疙暅雼り碃 氚濏様鞀惦媹雼�. 霕愴暅 鞚� 韽靺橃潃 氚滍枆鞚胳潣 歆�氚办棎 鞓來枼鞚� 氙胳範 鞚橂弰臧� 鞎勲嫎鞚� 頇曥澑頄堨姷雼堧嫟.
ReShape Lifesciences a re莽u un Schedule 13G amend茅 de la part de L1 Capital Global Opportunities Master Fund, Ltd., d茅clarant la propri茅t茅 b茅n茅ficiaire de 7 862 actions ordinaires sous-jacentes 脿 des warrants, repr茅sentant 0,33 % de la cat茅gorie sur la base de 2 385 960 actions en circulation apr猫s l'offre mentionn茅e dans le suppl茅ment au prospectus de l'茅metteur dat茅 du 9 juin 2025. Le d茅p么t pr茅cise que les actions sont d茅tenues par l'entit茅 des 卯les Ca茂mans et clarifie que David Feldman et Joel Arber sont administrateurs du fonds d茅clarant et peuvent 锚tre r茅put茅s d茅tenir b茅n茅ficiairement les titres, tout en d茅clinant toutefois cette propri茅t茅 脿 d'autres fins. Il est en outre confirm茅 que la position n'a pas pour but d'influencer le contr么le de l'茅metteur.
ReShape Lifesciences erhielt eine ge盲nderte Schedule-13G-Meldung von L1 Capital Global Opportunities Master Fund, Ltd., die den wirtschaftlichen Eigentum an 7.862 Stammaktien, die Optionsscheinen zugrunde liegen, meldet, was 0,33 % der Klasse auf Basis von 2.385.960 ausstehenden Aktien nach dem in der Prospektnachschrift des Emittenten vom 9. Juni 2025 genannten Angebot entspricht. Die Meldung gibt an, dass die Aktien von der Kaiman-Inseln-Gesellschaft gehalten werden, und stellt klar, dass David Feldman und Joel Arber Direktoren des meldenden Fonds sind und als wirtschaftliche Eigent眉mer der Wertpapiere gelten k枚nnten, diese Eigent眉merschaft jedoch f眉r andere Zwecke bestreiten. Weiterhin wird best盲tigt, dass die Position nicht dazu bestimmt ist, die Kontrolle 眉ber den Emittenten zu beeinflussen.
FAQ
How many ReShape Lifesciences (RSLS) shares does L1 Capital Global Opportunities Master Fund, Ltd. report owning?
What percentage of RSLS does the reported 7,862 shares represent?
When was the Schedule 13G/A filed for ReShape Lifesciences (RSLS)?
Who signed the Schedule 13G/A for L1 Capital Global Opportunities Master Fund, Ltd.?
Are the reported holdings intended to influence control of ReShape Lifesciences?
Are the reported shares direct holdings or underlying instruments?
